Stock AnalizRoivant Sciences Ltd. ROIV
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Roivant Sciences Ltd. (ROIV) is a healthcare company listed in the US with a market value of about $28.6B. In the twelve months to September 30, 2026 it had revenue of $41M and net income of -$344M, a net margin of -838.2%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -19% a year, a 5-year average ROIC of -11%.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenue | $41M | $8M | $29M | — | $32M | $55M | $24M |
| Net income | -$344M | -$300M | -$172M | $4.3B | -$1.0B | -$845M | -$809M |
| Free cash flow | -$39M | -$759M | -$844M | -$767M | -$856M | -$695M | -$558M |
| EPS (diluted) | $-0.57 | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 | $-1.28 |
| Net margin | -838.2% | -3629.2% | -592.0% | — | -3200.2% | -1528.9% | -3400.9% |
| ROIC | — | -8.8% | -16.6% | 69.3% | -44.8% | -55.0% | -41.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $50.82, 29% above the current price; targets range from $42.00 to $62.00; the consensus rating is “Strong buy”; expected EPS is $-1.47 for the fiscal year ending March 31, 2027.
Frequently asked questions
Does Roivant Sciences pay a dividend?
Not currently.
Is Roivant Sciences a good stock to buy?
We do not give buy or sell advice. Roivant Sciences scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.